(Q36456475)

14 August 2017

1 reference

title

Intermittent androgen deprivation: clinical experience and practical applications (English)

1 reference

14 August 2017

2

Celestia S Higano

1 reference

14 August 2017

Jonathan L Wright

1

1 reference

14 August 2017

Daniel W Lin

series ordinal

3

1 reference

14 August 2017

publication date

1 May 2006

1 reference

Urologic Clinics of North America

14 August 2017

published in

1 reference

14 August 2017

volume

33

1 reference

14 August 2017

issue

2

1 reference

14 August 2017

page(s)

167-79, vi

1 reference

Natural history of progression after PSA elevation following radical prostatectomy

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.013

Side effects of androgen deprivation therapy: monitoring and minimizing toxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.013

The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CapSURE), a national disease registry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.013

National practice patterns and time trends in androgen ablation for localized prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.013

A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.013

The development of androgen-independent prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.013

Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.013

The program of androgen-responsive genes in neoplastic prostate epithelium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.013

Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.013

Effects of intermittent androgen suppression on the stem cell composition and the expression of the TRPM-2 (clusterin) gene in the Shionogi carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.013

Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumour model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.013

Intermittent androgen suppression in the LuCaP 23.12 prostate cancer xenograft model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.013

Experimental treatment of prostatic cancer by intermittent hormonal therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.013

Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.013

Low-dose cyproterone acetate plus mini-dose diethylstilbestrol—A protocol for reversible medical castration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.013

Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: a pilot study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.013

Time to normalization of serum testosterone after 3-month luteinizing hormone-releasing hormone agonist administered in the neoadjuvant setting: implications for dosing schedule and neoadjuvant study consideration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.013

Prospective determination of the hormonal response after cessation of luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.013

A prospective analysis of time to normalization of serum testosterone after withdrawal of androgen deprivation therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.013

A prospective analysis of the time to normalization of serum androgens following 6 months of androgen deprivation therapy in patients on a randomized phase III clinical trial using limited hormonal therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.013

Intermittent androgen suppression in the treatment of metastatic prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.013

Intermittent androgen suppression in the management of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.013

Intermittent complete androgen blockade in PSA relapse after radical prostatectomy and incidental prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.013

Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.013

Intermittent androgen deprivation in prostate cancer patients: factors predictive of prolonged time off therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.013

Treatment of localized prostate cancer with intermittent triple androgen blockade: preliminary results in 110 consecutive patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.013

Intermittent endocrine therapy for advanced prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.013

Intermittent maximal androgen blockade in patients with metastatic prostate cancer: an EORTC feasibility study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.013

Bone mineral density in patients with prostate cancer without bone metastases treated with intermittent androgen suppression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.013

The Effects of Combined Androgen Blockade on Cognitive Function During the First Cycle of Intermittent Androgen Suppression in Patients With Prostate Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.013

One year follow-up study of the association between chemical castration, sex hormones, beta-amyloid, memory and depression in men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.013

A pilot study of intermittent androgen deprivation in advanced prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.013

Intermittent androgen deprivation after PSA-complete response as a strategy to reduce induction of hormone-resistant prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.013

Intermittent androgen suppression for prostate cancer: rationale and clinical experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.013

Intermittent androgen suppression in prostate cancer: the Canadian experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.013

Intermittent androgen suppression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.013

Intermittent androgen deprivation for clinically localized prostate cancer: initial experience.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.013

Intermittent androgen deprivation for biologic recurrence after radical prostatectomy: long-term experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.013

Intermittent androgen suppression in patients with prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.013

A 10-year clinical experience with intermittent hormonal therapy for prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.013

Intermittent Androgen Deprivation for Patients With Recurrent/Metastatic Prostate Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.013

Intermittent versus continuous total androgen blockade in the treatment of patients with advanced hormone-naive prostate cancer: results of a prospective randomized multicenter trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.013

Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.013

Improved Survival in Patients with Locally Advanced Prostate Cancer Treated with Radiotherapy and Goserelin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.013

Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3-year median followup from the Scandinavian Prostate Cancer Group Study Number 6.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.013

Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.013

Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.013

The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.013

Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.013

Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.013

Immunohistochemical analysis of Ki-67 antigen and Bcl-2 protein expression in prostate cancer: effect of neoadjuvant hormonal therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.013

Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.013

Intermediate end point for prostate cancer-specific mortality following salvage hormonal therapy for prostate-specific antigen failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.013

Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.013

Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.013

Preoperative PSA velocity is an independent prognostic factor for relapse after radical prostatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.013

National Cancer Institute intramural approach to advanced prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.013

10.1016/J.UCL.2005.12.013

7 January 2021

Identifiers

DOI

1 reference

14 August 2017

1 reference